Top

Published in:

Open Access 01-09-2023 | Lymphoma | Review and Perspectives

The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop

Authors: Alberto Zamò, Michiel van den Brand, Fina Climent, Laurence de Leval, Stefan Dirnhofer, Lorenzo Leoncini, Siok-Bian Ng, Sarah L. Ondrejka, Leticia Quintanilla-Martinez, Lorinda Soma, Andrew Wotherspoon

Published in: Virchows Archiv | Issue 3/2023

Abstract

Session 3 of the lymphoma workshop of the XXI joint meeting of the European Association for Haematopathology and the Society for Hematopathology took place in Florence, Italy, on September 22, 2022. The topics of this session were splenic and nodal marginal zone lymphomas, transformation in marginal zone lymphomas, and pediatric nodal marginal zone lymphomas and their differential diagnosis as well as related entities. Forty-two cases in these categories were submitted to the workshop, including splenic lymphomas (marginal zone and diffuse red pulp lymphomas), transformed marginal zone lymphomas (splenic and nodal), nodal marginal zone lymphomas with increased TFH-cells, and pediatric nodal marginal zone lymphomas. The case review highlighted some of the principal problems in the diagnosis of marginal zone lymphomas, including the difficulties in the distinction between splenic marginal zone lymphoma, splenic diffuse red pulp lymphoma, and hairy cell leukemia variant/splenic B-cell lymphoma with prominent nucleoli which requires integration of clinical features, immunophenotype, and morphology in blood, bone marrow, and spleen; cases of marginal zone lymphoma with markedly increased TFH-cells, simulating a T-cell lymphoma, where molecular studies (clonality and mutation detection) can help to establish the final diagnosis; the criteria for transformation of marginal zone lymphomas, which are still unclear and might require the integration of morphological and molecular data; the concept of an overlapping spectrum between pediatric nodal marginal zone lymphoma and pediatric-type follicular lymphoma; and the distinction between pediatric nodal marginal zone lymphoma and “atypical” marginal zone hyperplasia, where molecular studies are mandatory to correctly classify cases.

Available only for authorised users

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720–1748. https://doi.org/10.1038/s41375-022-01620-2CrossRefPubMedPubMedCentral

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G et al (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140:1229–1253. https://doi.org/10.1182/blood.2022015851CrossRefPubMedPubMedCentral

Laurent C, Cook JR, Yoshino T, Quintanilla-Martinez L, Jaffe ES (2022) Follicular lymphoma and marginal zone lymphoma: how many diseases? Virchows Arch. https://doi.org/10.1007/s00428-022-03432-2

Baseggio L, Traverse-Glehen A, Petinataud F, Callet-Bauchu E, Berger F, Ffrench M, Couris CM, Thieblemont C, Morel D, Coiffier B, Salles G, Felman P (2010) CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 95:604–612. https://doi.org/10.3324/haematol.2009.011049CrossRefPubMed

Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D (1994) The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 83:1558–1562CrossRefPubMed

Gailllard B, Cornillet-Lefebvre P, Le QH, Maloum K, Pannetier M, Lecoq-Lafon C, Grange B, Jondreville L, Michaux L, Nadal N, Ittel A, Luquet I, Struski S, Lefebvre C, Gaillard JB, Lafage-Pochitaloff M, Balducci E, Penther D, Barin C et al (2021) Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. Br J Haematol 193:72–82CrossRefPubMed

Munari E, Rinaldi M, Ambrosetti A, Bonifacio M, Bonalumi A, Chilosi M, Zamo A (2012) Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. Virchows Arch 461:677–685. https://doi.org/10.1007/s00428-012-1322-zCrossRefPubMedPubMedCentral

Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V, Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W et al (2012) Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features Cancer Res 72:5307-5316. https://doi.org/10.1158/0008-5472.CAN-12-1615

Metcalf RA, Monabati A, Vyas M, Roncador G, Gualco G, Bacchi CE, Younes SF, Natkunam Y, Freud AG (2014) Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. Hum Pathol 45:1730–1736. https://doi.org/10.1016/j.humpath.2014.04.004CrossRefPubMed

10.

Kanellis G, Roncador G, Arribas A, Mollejo M, Montes-Moreno S, Maestre L, Campos-Martin Y, Rios Gonzalez JL, Martinez-Torrecuadrada JL, Sanchez-Verde L, Pajares R, Cigudosa JC, Martin MC, Piris MA (2009) Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia 23:1847–1857. https://doi.org/10.1038/leu.2009.108CrossRefPubMed

11.

Wang Z, Cook JR (2019) IRTA1 and MNDA expression in marginal zone lymphoma: utility in differential diagnosis and implications for classification. Am J Clin Pathol 151:337–343. https://doi.org/10.1093/ajcp/aqy144CrossRefPubMed

12.

Righi S, Novero D, Godio L, Bertuzzi C, Bacci F, Agostinelli C, Sagramoso C, Rossi M, Piccioli M, Gazzola A, Mannu C, Roncador G, Sabattini E (2022) Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. Hum Pathol 124:67–75. https://doi.org/10.1016/j.humpath.2022.03.008CrossRefPubMed

13.

Favre R, Manzoni D, Traverse-Glehen A, Verney A, Jallades L, Callet-Bauchu E, Sujobert P, Salles G, Baseggio L (2018) Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. Int J Lab Hematol 40:e59–e62. https://doi.org/10.1111/ijlh.12824CrossRefPubMed

14.

Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Sole F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22:487–495. https://doi.org/10.1038/sj.leu.2405068CrossRefPubMed

15.

Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, Foa R, Pulsoni A, Dalla Favera R, Pileri S (2004) Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 363:1869–1870. https://doi.org/10.1016/S0140-6736(04)16356-3CrossRefPubMed

16.

Watkins AJ, Huang Y, Ye H, Chanudet E, Johnson N, Hamoudi R, Liu H, Dong G, Attygalle A, McPhail ED, Law ME, Isaacson PG, de Leval L, Wotherspoon A, Du MQ (2010) Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis. J Pathol 220:461–474. https://doi.org/10.1002/path.2665CrossRefPubMed

17.

Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U, Rancoita PM, De Campos CP, Forconi F, Gascoyne RD, Facchetti F, Ponzoni M, Govi S, Ferreri AJ, Mollejo M, Piris MA, Baldini L, Soulier J, Thieblemont C et al (2011) Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood 117:1595–1604. https://doi.org/10.1182/blood-2010-01-264275CrossRefPubMed

18.

Baliakas P, Strefford JC, Bikos V, Parry M, Stamatopoulos K, Oscier D (2015) Splenic marginal-zone lymphoma: ontogeny and genetics. Leuk Lymphoma 56:301–310. https://doi.org/10.3109/10428194.2014.919636CrossRefPubMed

19.

Fresquet V, Robles EF, Parker A, Martinez-Useros J, Mena M, Malumbres R, Agirre X, Catarino S, Arteta D, Osaba L, Mollejo M, Hernandez-Rivas JM, Calasanz MJ, Daibata M, Dyer MJ, Prosper F, Vizcarra E, Piris MA, Oscier D, Martinez-Climent JA (2012) High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. Br J Haematol 158:712–726. https://doi.org/10.1111/j.1365-2141.2012.09226.xCrossRefPubMed

20.

Novara F, Arcaini L, Merli M, Passamonti F, Zibellini S, Rizzi S, Rattotti S, Rumi E, Pascutto C, Vetro A, Astori C, Boveri E, Lucioni M, Paulli M, Zuffardi O, Lazzarino M (2009) High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. Hum Pathol 40:1628–1637. https://doi.org/10.1016/j.humpath.2009.01.025CrossRefPubMed

21.

Arcaini L, Rossi D, Paulli M (2016) Splenic marginal zone lymphoma: from genetics to management. Blood 127:2072–2081. https://doi.org/10.1182/blood-2015-11-624312CrossRefPubMed

22.

Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, Bolli N, Grove C, Moody S, Escudero-Ibarz L, Gundem G, Brugger K, Xue X, Mi E, Bench A, Scott M, Liu H, Follows G, Robles EF et al (2015) KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia 29:1177–1185. https://doi.org/10.1038/leu.2014.330CrossRefPubMed

23.

Jaramillo Oquendo C, Parker H, Oscier D, Ennis S, Gibson J, Strefford JC (2019) Systematic review of somatic mutations in splenic marginal zone lymphoma. Sci Rep 9:10444. https://doi.org/10.1038/s41598-019-46906-1CrossRefPubMedPubMedCentral

24.

Parry M, Rose-Zerilli MJ, Ljungstrom V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, Mciver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R et al (2015) Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res 21:4174–4183. https://doi.org/10.1158/1078-0432.CCR-14-2759CrossRefPubMedPubMedCentral

25.

Piva R, Deaglio S, Fama R, Buonincontri R, Scarfo I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E et al (2015) The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia 29:503–507. https://doi.org/10.1038/leu.2014.294CrossRefPubMed

26.

Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbo F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A et al (2016) The genetics of nodal marginal zone lymphoma. Blood 128:1362–1373. https://doi.org/10.1182/blood-2016-02-696757CrossRefPubMedPubMedCentral

27.

Vela V, Juskevicius D, Dirnhofer S, Menter T, Tzankov A (2022) Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin. Virchows Arch 480:403–413. https://doi.org/10.1007/s00428-021-03186-3CrossRefPubMed

28.

Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, Huebner-Chan DR, Bailey NG, Yang DT, Bhagat G, Miranda RN, Bahler DW, Medeiros LJ, Lim MS, Elenitoba-Johnson KS (2012) Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 209:1553–1565. https://doi.org/10.1084/jem.20120910CrossRefPubMedPubMedCentral

29.

Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC (2013) Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One 8:e83244. https://doi.org/10.1371/journal.pone.0083244CrossRefPubMedPubMedCentral

30.

Peveling-Oberhag J, Wolters F, Doring C, Walter D, Sellmann L, Scholtysik R, Lucioni M, Schubach M, Paulli M, Biskup S, Zeuzem S, Kuppers R, Hansmann ML (2015) Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. BMC Cancer 15:773. https://doi.org/10.1186/s12885-015-1766-zCrossRefPubMedPubMedCentral

31.

Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Fama R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J et al (2012) The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 209:1537–1551. https://doi.org/10.1084/jem.20120904CrossRefPubMedPubMedCentral

32.

Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L et al (2022) Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood 139:732–747. https://doi.org/10.1182/blood.2021012386CrossRefPubMed

33.

Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, Pasqualucci L, Bhagat G, Bertoni F (2009) The NF-kappaB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 113:4918–4921. https://doi.org/10.1182/blood-2008-08-174110CrossRefPubMedPubMedCentral

34.

Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I et al (2011) Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 118:4930–4934. https://doi.org/10.1182/blood-2011-06-359166CrossRefPubMed

35.

Martinez-Lopez A, Curiel-Olmo S, Mollejo M, Cereceda L, Martinez N, Montes-Moreno S, Almaraz C, Revert JB, Piris MA (2015) MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol 39:644–651. https://doi.org/10.1097/PAS.0000000000000411CrossRefPubMed

36.

Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L et al (2010) Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 116:1479–1488. https://doi.org/10.1182/blood-2010-02-267476CrossRefPubMed

37.

Deaglio S, Vaisitti T (2022) A new taxonomy for splenic marginal zone lymphoma. Blood 139:644–645. https://doi.org/10.1182/blood.2021014198CrossRefPubMed

38.

Campos-Martin Y, Martinez N, Martinez-Lopez A, Cereceda L, Casado F, Algara P, Oscier D, Menarguez FJ, Garcia JF, Piris MA, Mollejo M (2017) Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma. Haematologica 102:e310–e312. https://doi.org/10.3324/haematol.2016.161711CrossRefPubMedPubMedCentral

39.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dorken B et al (2014) Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med 20:87–92. https://doi.org/10.1038/nm.3435CrossRefPubMed

40.

Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, Montalban C, Matutes E, Wotherspoon A, Piris MA (2010) Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica 95:1122–1129. https://doi.org/10.3324/haematol.2009.013714CrossRefPubMedPubMedCentral

41.

Mollejo M, Algara P, Mateo MS, Sanchez-Beato M, Lloret E, Medina MT, Piris MA (2002) Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology 40:22–30. https://doi.org/10.1046/j.1365-2559.2002.01314.xCrossRefPubMed

42.

Papadaki T, Stamatopoulos K, Belessi C, Pouliou E, Parasi A, Douka V, Laoutaris N, Fassas A, Anagnostopoulos A, Anagnostou D (2007) Splenic marginal-zone lymphoma: one or more entities? A histologic, immunohistochemical, and molecular study of 42 cases. Am J Surg Pathol 31:438–446. https://doi.org/10.1097/01.pas.0000213419.08009.b0CrossRefPubMed

43.

Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud JP, Salles G, Coiffier B, Berger F, Felman P (2008) Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 111:2253–2260. https://doi.org/10.1182/blood-2007-07-098848CrossRefPubMed

44.

Traverse-Glehen A, Baseggio L, Salles G, Coiffier B, Felman P, Berger F (2012) Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. Discov Med 13:253–265PubMed

45.

Yilmaz E, Chhina A, Nava VE, Aggarwal A (2021) A review on splenic diffuse red pulp small B-cell lymphoma. Curr Oncol 28:5148–5154. https://doi.org/10.3390/curroncol28060431CrossRefPubMedPubMedCentral

46.

Baseggio L, Traverse-Glehen A, Callet-Bauchu E, Morel D, Magaud JP, Berger F, Salles G, Felman P (2011) Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). Hematol Oncol 29:47–51. https://doi.org/10.1002/hon.957CrossRefPubMed

47.

Mendes LS, Attygalle A, Matutes E, Wotherspoon A (2013) Annexin A1 expression in a splenic diffuse red pulp small B-cell lymphoma: report of the first case. Histopathology 63:590–593. https://doi.org/10.1111/his.12179CrossRefPubMed

48.

Curiel-Olmo S, Mondejar R, Almaraz C, Mollejo M, Cereceda L, Mares R, Derdak S, Campos-Martin Y, Batlle A, Gonzalez de Villambrosia S, Gut M, Blanc J, Traverse-Glehen A, Verney A, Baseggio L, Camacho FI, Wotherspoon A, Stamatopoulos K, Xochelli A et al (2017) Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. Blood 129:1042–1045. https://doi.org/10.1182/blood-2016-11-751024CrossRefPubMed

49.

Ozkaya N, Jaffe ES (2022) Splenic diffuse red pulp small B-cell lymphoma with cyclin D3 expression. Blood 140:793. https://doi.org/10.1182/blood.2022016694CrossRefPubMedPubMedCentral

50.

Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado D, Levy N, Beroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles G, Traverse-Glehen A (2017) Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica 102:1758–1766. https://doi.org/10.3324/haematol.2016.160192CrossRefPubMedPubMedCentral

51.

Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, Nadeu F, Enjuanes A, Clot G, Costa D, Carrio A, Villamor N, Colomer D, Martinez A, Bens S, Siebert R, Wotherspoon A, Bea S, Matutes E, Campo E (2016) NOTCH1, TP53, and MAP2K1 mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease. Am J Surg Pathol 40:192–201. https://doi.org/10.1097/PAS.0000000000000523CrossRefPubMed

52.

Traverse-Glehen A, Verney A, Gazzo S, Jallades L, Chabane K, Hayette S, Coiffier B, Callet-Bauchu E, Ffrench M, Felman P, Berger F, Baseggio L, Salles G (2017) Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies. Leuk Lymphoma 58:666–675. https://doi.org/10.1080/10428194.2016.1196813CrossRefPubMed

53.

Baseggio L, Geay MO, Gazzo S, Berger F, Traverse-Glehen A, Ffrench M, Hayette S, Callet-Bauchu E, Verney A, Morel D, Jallades L, Magaud JP, Salles G, Felman P (2012) In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia. Br J Haematol 158:489–498. https://doi.org/10.1111/j.1365-2141.2012.09178.xCrossRefPubMed

54.

Matutes E, Martinez-Trillos A, Campo E (2015) Hairy cell leukaemia-variant: disease features and treatment. Best Pract Res Clin Haematol 28:253–263. https://doi.org/10.1016/j.beha.2015.09.002CrossRefPubMed

55.

Matutes E (2021) Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021? Expert Rev Hematol 14:355–363. https://doi.org/10.1080/17474086.2021.1908121CrossRefPubMed

56.

Del Giudice I, Matutes E, Morilla R, Morilla A, Owusu-Ankomah K, Rafiq F, A’Hern R, Delgado J, Bazerbashi MB, Catovsky D (2004) The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 89:303–308PubMed

57.

Shao H, Calvo KR, Gronborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM (2013) Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 37:401–409. https://doi.org/10.1016/j.leukres.2012.11.021CrossRefPubMedPubMedCentral

58.

Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M (2011) Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol 136:625–630. https://doi.org/10.1309/AJCPKUM9J4IXCWEUCrossRefPubMed

59.

Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS (2014) High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 46:8–10. https://doi.org/10.1038/ng.2828CrossRefPubMed

60.

Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hullein J, Walther T, Wang L, Lu SX, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS et al (2017) Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood 130:1644–1648. https://doi.org/10.1182/blood-2017-01-765107CrossRefPubMedPubMedCentral

61.

Mason EF, Brown RD, Szeto DP, Gibson CJ, Jia Y, Garcia EP, Jacobson CA, Dal Cin P, Kuo FC, Pinkus GS, Lindeman NI, Sholl LM, Aster JC, Morgan EA (2017) Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leuk Lymphoma 58:233–236. https://doi.org/10.1080/10428194.2016.1185786CrossRefPubMed

62.

Oscier D, Stamatopoulos K, Mirandari A, Strefford J (2022) The genomics of hairy cell leukaemia and splenic diffuse red pulp lymphoma. Cancers (Basel):14. https://doi.org/10.3390/cancers14030697

63.

Hockley SL, Else M, Morilla A, Wotherspoon A, Dearden C, Catovsky D, Gonzalez D, Matutes E (2012) The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol 158:347–354. https://doi.org/10.1111/j.1365-2141.2012.09163.xCrossRefPubMed

64.

Behdad A, Bailey NG (2014) Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med 138:1295–1301. https://doi.org/10.5858/arpa.2014-0291-CCCrossRefPubMed

65.

Ponzoni M, Kanellis G, Pouliou E, Baliakas P, Scarfo L, Ferreri AJ, Doglioni C, Bikos V, Dagklis A, Anagnostopoulos A, Ghia P, Stamatopoulos K, Papadaki T (2012) Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? Am J Surg Pathol 36:1609–1618. https://doi.org/10.1097/PAS.0b013e318271243dCrossRefPubMed

66.

Doglioni C, Ponzoni M, Ferreri AJ, Savio A, Gruppo Italiano Patologi Apparato D, Societa Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology Id (2011) Gastric lymphoma: the histology report. Dig Liver Dis 43(Suppl 4):S310–S318. https://doi.org/10.1016/S1590-8658(11)60587-2CrossRefPubMed

67.

Nathwani BN, Anderson JR, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Muller-Hermelink HK, Ullrich FA, Weisenburger DD (1999) Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin’s Lymphoma Classification Project J Clin Oncol 17:2486–2492. https://doi.org/10.1200/JCO.1999.17.8.2486CrossRefPubMed

68.

Bastidas-Mora G, Bea S, Navarro A, Gine E, Costa D, Delgado J, Baumann T, Magnano L, Rivas-Delgado A, Villamor N, Colomer D, Lopez-Guerra M, Rozman M, Balague O, Martinez D, Baptista MJ, Escoda L, Alcoceba M, Blanes M et al (2022) Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. Br J Haematol 196:146–155. https://doi.org/10.1111/bjh.17815CrossRefPubMed

69.

Grau M, Lopez C, Navarro A, Frigola G, Nadeu F, Clot G, Bastidas G, Alcoceba M, Baptista MJ, Blanes M, Colomer D, Costa D, Domingo-Domenech E, Enjuanes A, Escoda L, Forcada P, Gine E, Lopez-Guerra M, Ramon O et al (2023) Unraveling the genetics of transformed splenic marginal zone lymphoma. Blood Adv. https://doi.org/10.1182/bloodadvances.2022009415

70.

Aguilera NS, Howard LN, Brissette MD, Abbondanzo SL (1996) Hodgkin’s disease and an extranodal marginal zone B-cell lymphoma in the small intestine: an unusual composite lymphoma. Mod Pathol 9:1020–1026PubMed

71.

Elmahy H, Hawley I, Beard J (2007) Composite splenic marginal zone lymphoma and classic Hodgkin lymphoma -- an unusual combination. Int J Lab Hematol 29:461–463. https://doi.org/10.1111/j.1365-2257.2006.00859.xCrossRefPubMed

72.

Harada S, Kalla H, Balasubramanian M, Brodsky I, Gladstone D, Hou JS (2008) Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen. Ann Diagn Pathol 12:212–216. https://doi.org/10.1016/j.anndiagpath.2006.12.005CrossRefPubMed

73.

Menter T, Dirnhofer S, Tzankov A (2019) Transformation of a splenic marginal zone lymphoma into classic Hodgkin lymphoma. J Clin Pathol 72:391–392. https://doi.org/10.1136/jclinpath-2018-205678CrossRefPubMed

74.

Rosenquist R, Roos G, Erlanson M, Kuppers R, Brauninger A, Hansmann ML (2004) Clonally related splenic marginal zone lymphoma and Hodgkin lymphoma with unmutated V gene rearrangements and a 15-yr time gap between diagnoses. Eur J Haematol 73:210–214. https://doi.org/10.1111/j.1600-0609.2004.00283.xCrossRefPubMed

75.

Algashaamy K, Tan Y, Mackrides N, Alencar A, Peng JH, Rosenblatt J, Alderuccio JP, Lossos IS, Vega F, Chapman J (2018, 2018) Splenic B-cell lymphomas with diffuse cyclin D1 protein expression and increased prolymphocytic cells: a previously unrecognized diagnostic pitfall. Case Rep Hematol:5761953. https://doi.org/10.1155/2018/5761953

76.

Bob R, Falini B, Marafioti T, Paterson JC, Pileri S, Stein H (2013) Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of IRTA1 and T-bet as positive markers. Histopathology 63:482–498. https://doi.org/10.1111/his.12160CrossRefPubMed

77.

Vroobel KM, O’Connor S, Cunningham D, Wren D, Sharma B, Wotherspoon A, Attygalle AD (2019) Florid T follicular helper cell hyperplasia associated with extranodal marginal zone lymphoma: a diagnostic pitfall which may mimic T cell lymphoma. Histopathology 75:287–290. https://doi.org/10.1111/his.13858CrossRefPubMed

78.

Egan C, Laurent C, Alejo JC, Pileri S, Campo E, Swerdlow SH, Piris M, Chan WC, Warnke R, Gascoyne RD, Xi L, Raffeld M, Pittaluga S, Jaffe ES (2020) Expansion of PD1-positive T cells in nodal marginal zone lymphoma: a potential diagnostic pitfall. Am J Surg Pathol 44:657–664. https://doi.org/10.1097/PAS.0000000000001414CrossRefPubMedPubMedCentral

79.

Hurwitz SN, Caponetti GC, Smith L, Qualtieri J, Morrissette JJD, Lee WS, Frank DM, Bagg A (2021) Mutational analysis reinforces the diagnosis of nodal marginal zone lymphoma with robust PD1-positive T-cell hyperplasia. Am J Surg Pathol 45:143–145. https://doi.org/10.1097/PAS.0000000000001515CrossRefPubMed

80.

Taddesse-Heath L, Pittaluga S, Sorbara L, Bussey M, Raffeld M, Jaffe ES (2003) Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol 27:522–531. https://doi.org/10.1097/00000478-200304000-00014CrossRefPubMedPubMedCentral

81.

Swerdlow SH (2004) Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am J Clin Pathol 122:S98–S109. https://doi.org/10.1309/4BKNAKE4D7CT3C1BCrossRefPubMed

82.

Gitelson E, Al-Saleem T, Robu V, Millenson MM, Smith MR (2010) Pediatric nodal marginal zone lymphoma may develop in the adult population. Leuk Lymphoma 51:89–94. https://doi.org/10.3109/10428190903349670CrossRefPubMedPubMedCentral

83.

Quintanilla-Martinez L, Sander B, Chan JK, Xerri L, Ott G, Campo E, Swerdlow SH (2016) Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Arch 468:141–157. https://doi.org/10.1007/s00428-015-1855-zCrossRefPubMed

84.

Rizzo KA, Streubel B, Pittaluga S, Chott A, Xi L, Raffeld M, Jaffe ES (2010) Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR. Mod Pathol 23:866–873. https://doi.org/10.1038/modpathol.2010.63CrossRefPubMedPubMedCentral

85.

Attygalle AD, Liu H, Shirali S, Diss TC, Loddenkemper C, Stein H, Dogan A, Du MQ, Isaacson PG (2004) Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood 104:3343–3348. https://doi.org/10.1182/blood-2004-01-0385CrossRefPubMed

86.

Kluin PM, Langerak AW, Beverdam-Vincent J, Geurts-Giele WR, Visser L, Rutgers B, Schuuring E, Van Baarlen J, Lam KH, Seldenrijk K, Kibbelaar RE, de Wit P, Diepstra A, Rosati S, van Noesel MM, Zwaan CM, Hunting JC, Hoogendoorn M, van der Gaag EJ et al (2015) Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder? J Pathol 236:302–314. https://doi.org/10.1002/path.4524CrossRefPubMed

87.

Ozawa MG, Bhaduri A, Chisholm KM, Baker SA, Ma L, Zehnder JL, Luna-Fineman S, Link MP, Merker JD, Arber DA, Ohgami RS (2016) A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol 29:1212–1220. https://doi.org/10.1038/modpathol.2016.102CrossRefPubMedPubMedCentral

88.

Salmeron-Villalobos J, Egan C, Borgmann V, Muller I, Gonzalez-Farre B, Ramis-Zaldivar JE, Nann D, Balague O, Lopez-Guerra M, Colomer D, Oschlies I, Klapper W, Glaser S, Ko YH, Bonzheim I, Siebert R, Fend F, Pittaluga S, Campo E et al (2022) A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile. Blood Adv 6:4661–4674. https://doi.org/10.1182/bloodadvances.2022007322CrossRefPubMedPubMedCentral

89.

Lim S, Lim KY, Koh J, Bae JM, Yun H, Lee C, Kim YA, Paik JH, Jeon YK (2022) Pediatric-type indolent B-cell lymphomas with overlapping clinical, pathologic, and genetic features. Am J Surg Pathol 46:1397–1406. https://doi.org/10.1097/PAS.0000000000001932CrossRefPubMedPubMedCentral

90.

Lee J, Han JH, Lee CH, Park HS, Min SK, Lee H, Cho U, Yoon SE, Kim SJ, Kim WS, Cho J (2023) Comparison of histological and molecular features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Virchows Arch. https://doi.org/10.1007/s00428-023-03493-x

91.

Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva A et al (2017) Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol 139(597-606):e594. https://doi.org/10.1016/j.jaci.2016.06.021CrossRef

Title: The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop
Authors: Alberto Zamò
Michiel van den Brand
Fina Climent
Laurence de Leval
Stefan Dirnhofer
Lorenzo Leoncini
Siok-Bian Ng
Sarah L. Ondrejka
Leticia Quintanilla-Martinez
Lorinda Soma
Andrew Wotherspoon
Publication date: 01-09-2023
Publisher: Springer Berlin Heidelberg
Keyword: Lymphoma
Published in: Virchows Archiv / Issue 3/2023
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-023-03633-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas: a report of the 2022 EA4HP/SH lymphoma workshop

Cavity-based lymphomas: challenges and novel concepts

Evaluation of high-risk human papillomavirus in sinonasal papillomas and squamous cell carcinomas

Clinicopathological characteristics of gastric adenocarcinoma with enteroblastic differentiation and gastric adenocarcinoma with enteroblastic marker expression

Recurrent gastric amphicrine tumor with neuroendocrine and pancreatic acinar cell differentiation and somatic MEN1 inactivation arisen during immunotherapy

Correction to: The many faces of nodal and splenic marginal zone lymphomas